Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The triple viral + varicella vaccine-Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina refers to the combination of the trivalent measles, mumps, and rubella (MMR) vaccine with the varicella (chickenpox) vaccine as utilized in clinical research by the Jordi Gol i Gurina Primary Care Research Institute (IDIAPJGol). This combination, often administered as a single quadrivalent injection (MMRV) or as co-administered separate injections, is a live-attenuated viral vaccine designed to induce active immunity against four major pediatric viral diseases. In the specific context of the IDIAPJGol study, this vaccine combination serves as a procedural stimulus to evaluate the efficacy of virtual reality (VR) as a non-pharmacological intervention for reducing pain and anxiety in children during routine immunization. The vaccine works by introducing weakened forms of the Measles morbillivirus, Mumps orthorubulavirus, Rubella virus, and Human alphaherpesvirus 3, thereby stimulating the production of specific antibodies and memory cells to prevent future infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triple viral + varicella vaccine-Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina.